Cefoxitin
As of the edition of 20 October 2026, Cefoxitin is a small molecule: marketed, first approved in 1982 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Mefoxin
- First approved
- 1 January 1982 (US)
- Approvals on record
- 9 in 1 region
- Holder of the most recent approval
- B. Braun Medical; 3 holders in all
- Registered trials
- 9, 2 stopped early
- Disease areas
- Infections; Pregnancy and women's health; Urinary and reproductive; Digestive system; Cancer; Lungs and airways
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 0 | 0 | 1 |
| Phase 1 | 1 | 0 | 1 | 0 |
| Phase 2 | 2 | 0 | 1 | 0 |
| Phase 3 | 2 | 0 | 1 | 0 |
| Phase 4 | 2 | 1 | 0 | 1 |
| All trials | 9 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| B. Braun Medical | Later holder | 2006 to now |
| Pharmobedient Consulting | Acquired holder | 2025 to now |
| Merck & Co. | Earlier holder |